Ipilimumab in advanced melanoma: Reports of long-lasting responses

Melanoma Research

Volumn 22, Issue 3, 2012, Pages 263-270

  Farolfi, Alberto ^a   Ridolfi, Laura ^a   Guidoboni, Massimo ^a   Nicoletti, Stefania Vittoria Luisa ^a   Piciucchi, Sara ^b   Valmorri, Linda ^c   Costantini, Matteo ^d   Scarpi, Emanuela ^c   Amadori, Dino ^a   Ridolfi, Ruggero ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b Radiology Unit   (Italy)

^c Unit of Biostatistics and Clinical Trials   (Italy)

^d MORGAGNI PIERANTONI HOSPITAL   (Italy)

Author keywords

Advanced melanoma; Anti CTLA 4 monoclonal antibody therapy; Immune related response criteria; Ipilimumab; Melanoma treatment; Predictive factors of response

Indexed keywords

IPILIMUMAB;

ADULT; AGED; ARTICLE; ASTHENIA; DERMATITIS; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DYSTHYROIDISM; FEMALE; FEVER; HUMAN; IMMUNE RESPONSE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PRURITUS; THYROID DISEASE; TREATMENT RESPONSE; TUMOR VOLUME; VITILIGO; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84860754987     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328353e65c     Document Type: Article

References (51)

1. Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer 2007; 109:455-464. (Pubitemid 46190953)
2. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199-6206.
3. Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 2009; 9:587-595.
4. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004; 351:998-1012.
5. Atallah E, Flaherty L. Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 2005; 6:185-193. (Pubitemid 40945448)
6. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004; 40:1825-1836. (Pubitemid 39036756)
7. Trinh VA. Current management of metastatic melanoma. Am J Health Syst Pharm 2008; 65 (Suppl 9):S3-S8.
8. Lee ML, Tomsu K, Von Eschen KB. Duration of survival for disseminated malignant melanoma: results of a meta-analysis. Melanoma Res 2000; 10:81-92. (Pubitemid 30127833)
9. Lui P, Cashin R, Machado M, Hemels M, Corey-Lisle PK, Einarson TR. Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev 2007; 33:665-680. (Pubitemid 350082665)
10. Petrella T, Quirt I, Verma S, Haynes AE, Charette M, Bak K. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev 2007; 33:484-496. (Pubitemid 47333669)
11. Hersey P, Bastholt L, Chiarion-Sileni V, Cinat G, Dummer R, Eggermont AM, et al. Small molecules and targeted therapies in distant metastatic disease. Ann Oncol 2009; 20 (Suppl 6):vi35-vi40.
12. Kefford R, Millward M, Hersey P, Brady B, Graham M, Johnson RG, et al. Phase II trial of tanespimycin (KOS-953), a heat shock protein-90 (Hsp90) inhibitor in patients with metastatic melanoma [Abstract]. J Clin Oncol (Meeting Abstracts) 2007; 25 (Suppl):8558.
13. Fecher LA, Cummings SD, Keefe MJ, Alani RM. Toward a molecular classification of melanoma. J Clin Oncol 2007; 25:1606-1620. (Pubitemid 46733089)
14. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008; 105:3041-3046. (Pubitemid 351723664)
15. Dummer R, Robert C, Chapman PB, Sosman JA, Middleton M, Bastholt L, et al. AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: an open-label, randomized, multicenter, phase II study [Abstract]. J Clin Oncol (Meeting Abstracts) 2008; 26 (Suppl):9033.
16. Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009; 27:2823-2830.
17. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24:4738-4745. (Pubitemid 46630937)
18. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464:431-435.
19. Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, et al. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 2010; 17:229-235.
20. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
21. Sondak VK, Sabel MS, Mule JJ. Allogeneic and autologous melanoma vaccines: where have we been and where are we going? Clin Cancer Res 2006; 12 (7 Pt 2):2337s-2341s.
22. Ridolfi R, Ridolfi L, Petrini M, Fiammenghi L, Riccobon A. Dendritic cell vaccination and immunostimulation in advanced melanoma. Expert Rev Vaccines 2003; 2:825-833. (Pubitemid 37541568)
23. Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 2009; 58:1-14.
24. Ridolfi R, Petrini M, Fiammenghi L, Stefanelli M, Ridolfi L, Ballardini M, et al. Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients. J Transl Med 2006; 4:36.
25. Schadendorf D, Algarra SM, Bastholt L, Cinat G, Dreno B, Eggermont AM, et al. Immunotherapy of distant metastatic disease. Ann Oncol 2009; 20 (Suppl 6):vi41-vi50.
26. Peggs KS, Segal NH, Allison JP. Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. Cancer Cell 2007; 12:192-199. (Pubitemid 47333423)
27. Inman BA, Frigola X, Dong H, Kwon ED. Costimulation, coinhibition and cancer. Curr Cancer Drug Targets 2007; 7:15-30. (Pubitemid 46345505)
28. Robert C, Ghiringhelli F. What is the role of cytotoxic T lymphocyteassociated antigen 4 blockade in patients with metastatic melanoma? Oncologist 2009; 14:848-861.
29. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 2008; 26:5275-5283.
30. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007; 110:2614-2627. (Pubitemid 350250330)
31. Ridolfi L, Ridolfi R. Anti-CTLA-4 therapy in melanoma: role of ipilimumab (MDX-010). Expert Rev Dermatol 2009; 4:199-210.
32. Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 2009; 27:1075-1081.
33. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009; 58:823-830.
34. Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs 2011; 29:489-498.
35. Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009; 15:5591-5598.
36. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155-164.
37. Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyteassociated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005; 12:1005-1016. (Pubitemid 41660676)
38. Agarwala SS. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma. Melanoma Res 2010; 20:1-10.
39. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15:7412-7420.
40. Kaplan EL, Meier P. Non parametric estimation for incomplete observation. J Am Stat Assoc 1958; 53:457-481.
41. Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 2008; 13 (Suppl 4):2-9.
42. Ribas A. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675, 206). Oncologist 2008; 13 (Suppl 4):10-15.
43. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 21:1712-1717.
44. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158-166. (Pubitemid 30036349)
45. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
46. Ribas A, Hauschild A, Kefford R, Gomez-Navarro J, Pavlov D, Marshall MA. Phase III, open-label, randomized, comparative study of tremelimumab (CP- 675, 206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma [Abstract]. J Clin Oncol (Meeting Abstracts) 2008; 26 (Suppl):LBA9011.
47. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13 (22 Pt 1):6681-6688. (Pubitemid 350206804)
48. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23:6043-6053.
49. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24:2283-2289. (Pubitemid 46630658)
50. Chin K, Ibrahim R, Berman D. Treatment guidelines for the management of immune-related adverse events in patients treated with ipilimumab, an anti- CTLA4 therapy [Abstract]. Ann Oncol 2008; 19 (Suppl 8):787P.
51. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007; 12:864-872. (Pubitemid 47328229)